Bone-derived soluble factors and laminin-511 cooperate to promote migration, invasion and survival of bone-metastatic breast tumor cells

Growth Factors

Volumn 32, Issue 2, 2014, Pages 63-73

  Denoyer, Delphine ^a   Kusuma, Nicole ^a   Burrows, Allan ^a   Ling, Xiawei ^a   Jupp, Lara ^a   Anderson, Robin L ^a,b,c   Pouliot, Normand ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b Department of Pathology ^*  (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

AKT 1 2; Bone metastasis; Breast cancer; Laminin 511; MMP 9; TGF 1

Indexed keywords

CHEMOKINE; CXCL16 CHEMOKINE; GELATINASE B; GROWTH ARREST SPECIFIC PROTEIN 6; GROWTH FACTOR; LAMININ 10; MACROPHAGE INFLAMMATORY PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCLEROPROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BREAST TUMOR; CELL DEATH; CELL INVASION; CELL KILLING; CELL MIGRATION; CELL SURVIVAL; CHEMOTAXIS; COLONY FORMATION; COLONY FORMING UNIT; CONTROLLED STUDY; DENSITOMETRY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; ZYMOGRAPHY;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HEK293 CELLS; HUMANS; LAMININ; MAP KINASE KINASE KINASES; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MICE; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84896927538     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2014.894037     Document Type: Article

References (53)

1. Adair-Kirk TL, Atkinson JJ, Kelley DG, Arch RH, Miner JH, Senior RM. 2005. A chemotactic peptide from laminin alpha 5 functions as a regulator of inflammatory immune responses via TNF alpha-mediated signaling. J Immunol 174:1621-1629.
2. Alam N, Goel HL, Zarif MJ, Butterfield JE, Perkins HM, Sansoucy BG, Sawyer TK, et al. 2007. The integrin-growth factor receptor duet. J Cell Physiol 213:649-653.
3. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. 2000. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 275:36803-36810. (Pubitemid 32002090)
4. Casimiro S, Guise TA, Chirgwin J. 2009. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 310: 71-81.
5. Chia J, Kusuma N, Anderson R, Parker B, Bidwell B, Zamurs L, Nice E, Pouliot N. 2007. Evidence for a role of tumor-derived laminin-511 in the metastatic progression of breast cancer. Am J Pathol 170: 2135-2148. (Pubitemid 47339285)
6. Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD, Cher ML. 2006. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12. Prostate 66:32-48. (Pubitemid 43005947)
7. Clezardin P. 2011. Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res 13:207 (1-9).
8. Coleman RE, Smith P, Rubens RD. 1998. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 77: 336-340. (Pubitemid 28029553)
9. Dai CY, Haqq CM, Puzas JE. 2006. Molecular correlates of site-specific metastasis. Semin Radiat Oncol 16:102-110.
10. Desantis C, Ma J, Bryan L, Jemal A. 2011. Breast cancer statistics, 2013. CA: J Clin 61:409-418.
11. Dittmar T, Heyder C, Gloria-Maercker E, Hatzmann W, Zanker KS. 2008. Adhesion molecules and chemokines: The navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin Exp Metastasis 25:11-32. (Pubitemid 351191223)
12. Doi M, Thyboll J, Kortesmaa J, Jansson K, Iivanainen A, Parvardeh M, Timpl R, et al. 2002. Recombinant human laminin-10 (alpha5beta1-gamma1). Production, purification, and migration-promoting activity on vascular endothelial cells. J Biol Chem 277:12741-12748. (Pubitemid 34952635)
13. Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, Stanley KL, et al. 2005. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 3:1-13. (Pubitemid 40189591)
14. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, Ishikawa Y, et al. 2007a. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 98:127-133. (Pubitemid 44803931)
15. Ehata S, Hanyu A, Hayashi M, Aburatani H, Kato Y, Fujime M, Saitoh M, et al. 2007b. Transforming growth factor-beta promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription factor DEC1. Cancer Res 67:9694-9703. (Pubitemid 47621216)
16. Futakuchi M, Nannuru KC, Varney ML, Sadanandam A, Nakao K, Asai K, Shirai T, et al. 2009. Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation. Cancer Sci 100:71-81.
17. Gustafsson A, Martuszewska D, Johansson M, Ekman C, Hafizi S, Ljungberg B, Dahlback B. 2009. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res 15:4742-4749.
18. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, et al. 2010. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 70:1544-1554.
19. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA: Cancer J Clin 61:69-90.
20. Jiang BH, Liu LZ. 2009. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 102:19-65.
21. Jin F, Irshad S, Yu W, Belakavadi M, Chekmareva M, Ittmann MM, Abate-Shen C, Fondell JD. 2013. ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity. Mol Cancer Res 11:736-747.
22. Joyce JA, Pollard JW. 2009. Microenvironmental regulation of metastasis. Nat Rev Cancer 9:239-252.
23. Katagiri M, Hakeda Y, Chikazu D, Ogasawara T, Takato T, Kumegawa M, Nakamura K, Kawaguchi H. 2001. Mechanism of stimulation of osteoclastic bone resorption through Gas6/Tyro 3, a receptor tyrosine kinase signaling, in mouse osteoclasts. J Biol Chem 276:7376-7382.
24. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. 2007. Molecular biology of bone metastasis. Mol Cancer Ther 6:2609-2617. (Pubitemid 350058141)
25. Kochetkova M, Kumar S, McColl SR. 2009. Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death Differ 16:664-673.
26. Kusuma N, Anderson RL, Pouliot N. 2011. Laminin alpha5-derived peptides modulate the properties of metastatic breast tumour cells. Clin Exp Metastasis 28:909-921.
27. Kusuma N, Denoyer D, Eble JA, Redvers RP, Parker BS, Pelzer R, Anderson RL, Pouliot N. 2012. Integrin-dependent response to laminin-511 regulates breast tumor cell invasion and metastasis. Int J Cancer 130:555-566.
28. Lee WJ, Chen WK, Wang CJ, Lin WL, Tseng TH. 2008. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol 226: 178-191.
29. Lindsley CW, Barnett SF, Yaroschak M, Bilodeau MT, Layton ME. 2007. Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr Top Med Chem 7:1349-1363. (Pubitemid 47484764)
30. Mebratu Y, Tesfaigzi Y. 2009. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle 8:1168-1175.
31. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. 2002. Regulation of Raf-Akt Cross-talk. J Biol Chem 277:31099-31106. (Pubitemid 34970815)
32. Mourskaia AA, Dong Z, Ng S, Banville M, Zwaagstra JC, O'Connor-McCourt MD, Siegel PM. 2009. Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone. Oncogene 28:1005-1015.
33. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, et al. 2001. Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56. (Pubitemid 32225831)
34. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, et al. 2002. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109: 1551-1559. (Pubitemid 34663517)
35. Nam JS, Suchar AM, Kang MJ, Stuelten CH, Tang B, Michalowska AM, Fisher LW, et al. 2006. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 66: 6327-6335.
36. Nguyen DX, Bos PD, Massague J. 2009. Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 9:274-284.
37. Ono K, Kamiya S, Akatsu T, Nakamura C, Li M, Amizuka N, Matsumoto K, et al. 2006. Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line, BALB/c-MC. Bone 39:27-34. (Pubitemid 43831769)
38. Patel LR, Camacho DF, Shiozawa Y, Pienta KJ, Taichman RS. 2011. Mechanisms of cancer cell metastasis to the bone: A multistep process. Future Oncol 7:1285-1297.
39. Pouliot N, Kusuma N. 2013. Laminin-511: A multi-functional adhesion protein regulating cell migration, tumor invasion and metastasis. Cell Adh Migr 7:142-149.
40. Sawabu T, Seno H, Kawashima T, Fukuda A, Uenoyama Y, Kawada M, Kanda N, et al. 2007. Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Mol Carcinog 46:155-164.
41. Sheng S, Qiao M, Pardee AB. 2009. Metastasis and AKT activation. J Cell Physiol 218:451-454.
42. Shin I, Bakin AV, Rodeck U, Brunet A, Arteaga CL. 2001. Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell 12:3328-3339. (Pubitemid 33108468)
43. Sloan EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK, Anderson RL. 2006. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res 8:R20 (1-14).
44. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, et al. 2011. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 3: 192-222.
45. Suva LJ, Washam C, Nicholas RW, Griffin RJ. 2011. Bone metastasis: Mechanisms and therapeutic opportunities. Nat Rev Endocrinol 7: 208-218.
46. Tai KY, Shieh YS, Lee CS, Shiah SG, Wu CW. 2008. Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene 27:4044-4055.
47. Tan AR, Alexe G, Reiss M. 2009. Transforming growth factor-beta signaling: Emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat 115:453-495.
48. Tester AM, Ruangpanit N, Anderson RL, Thompson EW. 2000. MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits. Clin Exp Metastasis 18:553-560. (Pubitemid 32964317)
49. Theriault RL. 2012. Biology of bone metastases. Cancer Control: J Moffitt Cancer Center 19:92-101.
50. Uttamsingh S, Bao X, Nguyen KT, Bhanot M, Gong J, Chan JL, Liu F, et al. 2008. Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene 27:2626-2634. (Pubitemid 351550880)
51. Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, von Tengg-Kobligk H, Kiessling F, et al. 2006. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci USA 103:5799-5804.
52. Weilbaecher KN, Guise TA, McCauley LK. 2011. Cancer to bone: A fatal attraction. Nat Rev Cancer 11:411-425.
53. White DE, Muller WJ. 2007. Multifaceted roles of integrins in breast cancer metastasis. J Mammary Gland Biol Neoplasia 12:135-142. (Pubitemid 47215431)